Please assess the completion status of the following clinical trial:

Trial Title: Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Inform Consent~* Age \> 18 years~* Histologically or cytologically confirmed SCCHN~* Diagnosis of metastatic disease by the investigator and/or recurrent disease determined to be incurable by surgery or radiotherapy~* Subjects who have received radiation as primary therapy are eligible if radiation therapy treatment was completed \> 4 weeks prior to inclusion~* Subjects who have previously received chemotherapy as part of the initial multimodality treatment for locally advanced disease are eligible if the chemotherapy was completed \> 24 weeks prior to inclusion~* At least 1 unidimensionally measurable lesion of ≥ 20 mm using conventional techniques or ≥10 mm with spiral CT scan. Target lesions must not be chosen from a previously irradiated field unless there had been documented tumour progression in that lesion prior to inclusion~* Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 at screening~* Haematological function:~  * ANC ≥ 1.5 x 109 cells/L~ * Hemoglobin ≥ 9.0 g/dL~ * Platelet count ≥ 100 x 109/L~* Kidney function:~  o Adequate renal function with creatinine clearance ≥ 60 mL/min)~* Liver function:~  * AST ≤ 3 x ULN (if liver metastases, ≤ 5 x ULN)~ * ALT ≤ 3 x ULN (if liver metastases, ≤ 5 x ULN)~ * Bilirubin ≤ 2 x ULN~* Metabolic function:~  * Magnesium ≥ lower limit of normal,~ * Calcium ≥ lower limit of normal~Exclusion Criteria:~* Documented or symptomatic central nervous system metastases~* Nasopharyngeal carcinoma~* History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest scan~* History of another primary cancer, except:~  * Curatively treated in situ cervical cancer, or~ * Curatively resected non-melanoma skin cancer or~ * Other primary solid tumour curatively treated with no known active disease present and no treatment administered for ≥ 3 years prior to starting the study treatment. In that case confirmation of inclusion by the sponsor is required.~* Clinically significant cardiovascular disease ≤ 1 year prior to starting the study treatment~* Pulmonary embolism, deep vein thrombosis, or other significant thromboembolic event ≤ 8 weeks prior to starting the study treatment~* Symptomatic peripheral neuropathy of Grade ≥ 2 based on the CTCAE v3.0~* Subjects not recovered from all previous acute radiotherapy-related toxicities to ≤ grade 1~* History of severe skin disorder that in the opinion of the investigator may interfere with study conduct~* Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic hepatitis B infection~* Active infection requiring systemic treatment or any uncontrolled infection ≤ 14 days prior to starting the study treatment~* History of interstitial pneumonia or pulmonary fibrosis or signs of interstitial pneumonia or pulmonary fibrosis on the baseline chest X-ray.~* Known allergy or hypersensitivity to panitumumab, or other study medications.~* Prior anti epidermal growth factor receptor (EGFr) antibody therapy or treatment with small molecule EGFr inhibitors unless received as part of prior multimodality treatment and completed \> 24 weeks prior to starting the study treatment. In this case, the investigator should confirm that the subject had not presented any previous cetuximab-related infusion reaction \> grade 2.~* Subject is currently enrolled in or ≤ 30 days since ending other investigational device, investigational procedure, or drug study(s), or subject is receiving other investigational agent(s)~* Subjects requiring use of immunosuppressive agents, however, corticosteroids are allowed~* Man or woman of child-bearing potential who do not consent to use adequate contraceptive precautions during the course of the study, and for 6 months after the last study drug administration for women, and 3 months for men.~* Female subject who is pregnant or breast-feeding, or planning to become pregnant within 6 months after the end of treatment.~* Major surgery requiring general anesthesia/ spinal anesthesia and a significant incision ≤ 28 days or minor surgery ≤ 14 days prior to starting the study treatment. Subjects must have recovered from surgery-related toxicities.~* Subjects who do not wish to meet the study requirements or are unable to do so.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab + Paclitaxel (Type: EXPERIMENTAL): Treatment consisted of intravenous panitumumab 6 mg/kg q2w, administered in one hour the first day and in 30 minutes thereafter (if no infusional reaction was observed) plus intravenous paclitaxel 80 mg/m2 weekly administered one hour after panitumumab in one hour infusion, until progression or unacceptable toxicity. Panitumumab does not require prophylactic premedication from the first infusion. Paclitaxel was administered with: dexamethasone 10 mg, diphenhydramine 30 mg and antiH2 (cimetidine 300 mg or ranitidine 50 mg). Dose modifications of paclitaxel included 4.8 mg/kg (80% of the initial dose) and 3.6 mg/kg (60%) when recovered from a grade 3-4 skin toxicity to grade ≤2. Continuing paclitaxel on the day of the planned infusion required no grade ≥2 mucositis and hematologic recovery with an absolute neutrophil count ≥1,500/ml and a platelet count ≥75,000.

Based on this trial design, predict the completion outcome and termination type (if applicable).